Department of Pediatric Rheumatology, Ankara University School of Medicine, Ankara, Turkey.
Department of Pediatric Rheumatology and Nephrology, Ankara University School of Medicine, Ankara, Turkey.
J Clin Lab Anal. 2019 May;33(4):e22852. doi: 10.1002/jcla.22852. Epub 2019 Feb 4.
Familial Mediterranean fever (FMF) is the most common hereditary monogenic autoinflammatory disease caused by mutations in the MEFV gene. It is controversial whether E148Q alteration is an insignificant variant or a disease-causing mutation. The aim of this study was to evaluate the clinical features and disease severity of FMF patients carrying E148Q mutation.
Files of FMF patients were retrospectively evaluated. Patients with at least one E148Q mutation were included to the study. The clinical characteristics and disease severity of the patients who were carrying only E148Q mutation were compared with the patients who were compound heterozygous for E148Q and homozygous for M694V mutation.
The study group comprised 33 patients who were homozygous or heterozygous for E148Q; 34 with compound heterozygous E148Q mutations and 86 patients who had homozygous M694V mutation. Patients who had only E148Q mutation were found to have the oldest mean age of disease onset and lowest mean disease severity score. Attack frequency and colchicine doses were lower in patients with only E148Q mutation as compared with the other two groups. The frequency of clinical findings such as fever, abdominal pain, arthralgia, and arthritis among the three groups was similar.
Familial Mediterranean fever patients with only E148Q mutation are presenting with late-onset and milder disease course despite having similar clinical findings as compared with patients who had other mutations. Finally, we imply that E148Q is a mutation and colchicine treatment should be given.
家族性地中海热(FMF)是最常见的遗传性单基因自身炎症性疾病,由 MEFV 基因突变引起。E148Q 改变是否为无意义变异或致病突变存在争议。本研究旨在评估携带 E148Q 突变的 FMF 患者的临床特征和疾病严重程度。
回顾性评估 FMF 患者的档案。将至少携带一个 E148Q 突变的患者纳入研究。比较仅携带 E148Q 突变的患者与 E148Q 复合杂合子和 M694V 突变纯合子的患者的临床特征和疾病严重程度。
研究组包括 33 名 E148Q 纯合子或杂合子患者;34 名 E148Q 复合杂合子突变和 86 名 M694V 突变纯合子患者。仅携带 E148Q 突变的患者发病年龄最大,疾病严重程度评分最低。与其他两组相比,仅携带 E148Q 突变的患者的发作频率和秋水仙碱剂量较低。三组的发热、腹痛、关节痛和关节炎等临床发现的频率相似。
尽管与其他突变患者相比,仅携带 E148Q 突变的 FMF 患者具有相似的临床发现,但表现为发病晚、疾病过程较轻。最后,我们暗示 E148Q 是一种突变,应该给予秋水仙碱治疗。